Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Javier Morales, Jay H. Shubrook & Neil Skolnik. (2020) Practical guidance for use of oral semaglutide in primary care: a narrative review. Postgraduate Medicine 132:8, pages 687-696.
Read now
Read now
Ofri Mosenzon, Eden M. Miller & Mark L. Warren. (2020) Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients. Postgraduate Medicine 132:sup2, pages 37-47.
Read now
Read now
Frank Lavernia & Lawrence Blonde. (2020) Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes compared with other oral antihyperglycemic agents and placebo. Postgraduate Medicine 132:sup2, pages 15-25.
Read now
Read now
Maka S. Hedrington & Stephen N. Davis. (2019) Oral semaglutide for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 20:2, pages 133-141.
Read now
Read now
Emuella M. Flood, Kelly F. Bell, Marie C. de la Cruz & France M. Ginchereau-Sowell. (2017) Patient preferences for diabetes treatment attributes and drug classes. Current Medical Research and Opinion 33:2, pages 261-268.
Read now
Read now
Linda Nguyen, Patrick J Marshalek, Cory B Weaver, Kathy J Cramer, Scott E Pollard & Rae R Matsumoto. (2015) Off-label use of transmucosal ketamine as a rapid-acting antidepressant: a retrospective chart review. Neuropsychiatric Disease and Treatment 11, pages 2667-2673.
Read now
Read now
Suellen M. Curkendall, Nina Thomas, Kelly F. Bell, Paul L. Juneau & Audrey J. Weiss. (2013) Predictors of medication adherence in patients with type 2 diabetes mellitus. Current Medical Research and Opinion 29:10, pages 1275-1286.
Read now
Read now
Mette Bøgelund, Tina Vilsbøll, Jens Faber, Jan Erik Henriksen, Rasmus Prior Gjesing & Morten Lammert. (2011) Patient preferences for diabetes management among people with type 2 diabetes in Denmark – a discrete choice experiment. Current Medical Research and Opinion 27:11, pages 2175-2183.
Read now
Read now
Articles from other publishers (28)
Gianluigi Savarese, Abhinav Sharma, Christianne Pang, Richard Wood & Nima Soleymanlou. (2023) Patient preferences for newer oral therapies in type 2 diabetes. International Journal of Cardiology 371, pages 526-532.
Crossref
Crossref
Jason HY Wu, Kathy Trieu, Daisy Coyle, Liping Huang, Nirupama Wijesuriya, Kellie Nallaiah, Thomas Lung, Gian L Di Tanna, Miaobing Zheng, Dariush Mozaffarian, Freya MacMillan, David Simmons, Ted Wu, Stephen Twigg, Amanda Gauld, Maria Constantino, Margaret McGill, Jencia Wong & Bruce Neal. (2022) Testing the Feasibility and Dietary Impact of a “Produce Prescription” Program for Adults with Undermanaged Type 2 Diabetes and Food Insecurity in Australia. The Journal of Nutrition 152:11, pages 2409-2418.
Crossref
Crossref
Vanita R. Aroda, Lawrence Blonde & Richard E. Pratley. (2022) A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. Reviews in Endocrine and Metabolic Disorders 23:5, pages 979-994.
Crossref
Crossref
David A. Griffith, David J. Edmonds, Jean-Philippe Fortin, Amit S. Kalgutkar, J. Brent Kuzmiski, Paula M. Loria, Aditi R. Saxena, Scott W. Bagley, Clare Buckeridge, John M. Curto, David R. Derksen, João M. Dias, Matthew C. Griffor, Seungil Han, V. Margaret Jackson, Margaret S. Landis, Daniel Lettiere, Chris Limberakis, Yuhang Liu, Alan M. Mathiowetz, Jayesh C. PatelDavid W. Piotrowski, David A. Price, Roger B. Ruggeri & David A. Tess. (2022) A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor. Journal of Medicinal Chemistry 65:12, pages 8208-8226.
Crossref
Crossref
Christine A. Butts, Duncan I. Hedderley, Sheridan Martell, Hannah Dinnan, Susanne Middlemiss-Kraak, Barry J. Bunn, Tony K. McGhie & Ross E. Lill. (2022) Influence of oral administration of kukoamine A on blood pressure in a rat hypertension model. PLOS ONE 17:5, pages e0267567.
Crossref
Crossref
Beate Bittner & Johannes Schmidt. 2022. Formulation and Device Lifecycle Management of Biotherapeutics. Formulation and Device Lifecycle Management of Biotherapeutics
1
46
.
José Francisco Kerr Saraiva & Denise Franco. (2021) Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients. Cardiovascular Diabetology 20:1.
Crossref
Crossref
José Gerardo González-González, Alejandro Díaz González-Colmenero, Juan Manuel Millán-Alanís, Lyubov Lytvyn, Ricardo Cesar Solis, Reem A Mustafa, Suetonia C Palmer, Sheyu Li, Qiukui Hao, Neri Alejandro Alvarez-Villalobos, Per Olav Vandvik & René Rodríguez-Gutiérrez. (2021) Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT-2 inhibitors in adult patients with type 2 diabetes: a systematic review. BMJ Open 11:7, pages e049130.
Crossref
Crossref
Mohammed E. Al-Sofiani, Mohammed A. Batais, Essa Aldhafiri & Aus Alzaid. (2021) Pharmacological treatment of type 2 diabetes in Saudi Arabia: A consensus statement from the Saudi Society of Endocrinology and Metabolism (SSEM). Diabetes & Metabolic Syndrome: Clinical Research & Reviews 15:3, pages 891-899.
Crossref
Crossref
Ahil N. Ganesh, Carolyn Heusser, Sudhakar Garad & Manuel Vicente Sánchez-Félix. (2021) Patient-centric design for peptide delivery: Trends in routes of administration and advancement in drug delivery technologies. Medicine in Drug Discovery 9, pages 100079.
Crossref
Crossref
Kristina Boye, Melissa Ross, Reema Mody, Manige Konig & Heather Gelhorn. (2020)
Patients' preferences for
once‐daily
oral versus
once‐weekly
injectable diabetes medications: The
REVISE
study
. Diabetes, Obesity and Metabolism 23:2, pages 508-519.
Crossref
Crossref
Kohei Kaku, Koichi Kisanuki, Mari Shibata & Takashi Oohira. (2019) Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus. Drug Safety 42:11, pages 1311-1327.
Crossref
Crossref
James R Miner, Timothy I Melson, David Leiman, Harold S Minkowitz, Yu-Kun Chiang, Karen P DiDonato & Pamela P Palmer. (2019) Pooled Phase III safety analysis of sufentanil sublingual tablets for short-term treatment of moderate-to-severe acute pain. Pain Management 9:3, pages 259-271.
Crossref
Crossref
Ross W. Cheloha, Bingming Chen, Niyanta N. Kumar, Tomoyuki Watanabe, Robert G. Thorne, Lingjun Li, Thomas J. Gardella & Samuel H. Gellman. (2017) Development of Potent, Protease-Resistant Agonists of the Parathyroid Hormone Receptor with Broad β Residue Distribution. Journal of Medicinal Chemistry 60:21, pages 8816-8833.
Crossref
Crossref
Gagik R. Galstyan, Evgeniya A. Karataeva & Ekaterina A. Yudovich. (2017) Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes. Diabetes mellitus 20:4, pages 286-298.
Crossref
Crossref
Paresh Chaudhari, Carlos Vallarino, Ernest H. Law & Raafat Seifeldin. (2016) Evaluation of patients with type 2 diabetes mellitus receiving treatment during the pre-diabetes period: Is early treatment associated with improved outcomes?. Diabetes Research and Clinical Practice 122, pages 162-169.
Crossref
Crossref
Emily Reeve, Petra Denig, Sarah N. Hilmer & Ruud ter Meulen. (2016) The Ethics of Deprescribing in Older Adults. Journal of Bioethical Inquiry 13:4, pages 581-590.
Crossref
Crossref
Rossella E. Nappi, Santiago Palacios, Martire Particco & Nick Panay. (2016) The REVIVE (REal Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs) survey in Europe: Country-specific comparisons of postmenopausal women’s perceptions, experiences and needs. Maturitas 91, pages 81-90.
Crossref
Crossref
S. Haque & M.B. Davies. (2015) Oral thromboprophylaxis in patients with ankle fractures immobilized in a below the knee cast. Foot and Ankle Surgery 21:4, pages 266-268.
Crossref
Crossref
Matthew Reaney. (2015) The Need for a Tool to Assist Health Care Professionals and Patients in Making Medication Treatment Decisions in the Clinical Management of Type 2 Diabetes. Diabetes Spectrum 28:4, pages 227-229.
Crossref
Crossref
Sieta T. de Vries, Folgerdiena M. de Vries, Thijs Dekker, Flora M. Haaijer-Ruskamp, Dick de Zeeuw, Adelita V. Ranchor & Petra Denig. (2015) The Role of Patients’ Age on Their Preferences for Choosing Additional Blood Pressure-Lowering Drugs: A Discrete Choice Experiment in Patients with Diabetes. PLOS ONE 10:10, pages e0139755.
Crossref
Crossref
Jörg Lüdemann, Eva D. Dütting & Markus Dworak. (2015)
Patient preference and tolerability of a DPP-4 inhibitor
versus
a GLP-1 analog in patients with type 2 diabetes mellitus inadequately controlled with metformin: a 24-week, randomized, multicenter, crossover study
. Therapeutic Advances in Endocrinology and Metabolism 6:4, pages 141-148.
Crossref
Crossref
Jennifer D. Goldman-Levine. (2015) Combination Therapy When Metformin Is Not an Option for Type 2 Diabetes. Annals of Pharmacotherapy 49:6, pages 688-699.
Crossref
Crossref
Axel C. Mühlbacher & A. Kaczynski. (2015) Patientenpräferenzen in der medikamentösen Therapie von Diabetes Mellitus Typ 2Patients’ preferences in the medicamentous treatment of diabetes mellitus type 2. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 58:4-5, pages 452-466.
Crossref
Crossref
Abdullah Kutlar & Stephen H. Embury. (2014) Cellular Adhesion and the Endothelium. Hematology/Oncology Clinics of North America 28:2, pages 323-339.
Crossref
Crossref
Sreeram V. Ramagopalan, Radek Wasiak & Andrew P. Cox. (2014) Using Twitter to investigate opinions about multiple sclerosis treatments: a descriptive, exploratory study. F1000Research 3, pages 216.
Crossref
Crossref
B. Charbonnel, H. Steinberg, E. Eymard, L. Xu, P. Thakkar, V. Prabhu, M. J. Davies & S. S. Engel. (2013) Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial. Diabetologia 56:7, pages 1503-1511.
Crossref
Crossref
Marc Evans, Phil McEwan, Richard O’Shea & Lindsay George. (2012) A Retrospective, Case-Note Survey of Type 2 Diabetes Patients Prescribed Incretin-Based Therapies in Clinical Practice. Diabetes Therapy 4:1, pages 27-40.
Crossref
Crossref